Conclusion Developing novel approaches for defining oncogene addiction networks, coupled with specific combination of molecular targeted agents, will make it possible to achieve more effective and personalized molecular targeted therapy in human gliomas. Author details 1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.6 Tiantan Xili, Dongcheng District, Beijing 100050, China. Acknowledgements This work was supported by grants from National Key Project of Science and Technology Supporting Programs (No. 2007BAI05B08) and National selleckchem Natural Science Foundation
of China (No. 30772238 and 30730035). References 1. Mizuarai S, Irie H, Schmatz DM, Kotani H: Integrated genomic and pharmacological
approaches to identify synthetic lethal genes as cancer therapeutic targets. Curr Mol Med 2008, 8:774–783.PubMedCrossRef 2. Weinstein IB, Joe AK: Mechanisms of disease: Oncogene addiction–a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 2006, 3:448–457.PubMedCrossRef 3. Weinstein IB, Joe A: Oncogene addiction. Cancer Res 2008, 68:3077–3080.PubMedCrossRef 4. Weinstein IB: Cancer: Addiction to oncogenes–the Achilles heal of cancer. Science 2002, 297:63–64.PubMedCrossRef 5. Garber K: New insights into oncogene addiction found. J Natl Cancer Inst 2007, 99:264–265, 269.PubMedCrossRef 6. Felsher DW: MYC Inactivation Elicits Oncogene Addiction through Both Tumor Cell-Intrinsic and Host-Dependent Mechanisms. Genes Cancer 2010, 1:597–604.PubMedCrossRef Selumetinib Doxorubicin datasheet 7. Lee JT, Shan J, Gu W: Targeting the degradation of cyclin D1 will help to eliminate oncogene addiction. Cell Cycle 2010, 9:857–858.PubMedCrossRef 8. Comoglio PM, Giordano S, Trusolino L: Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008, 7:504–516.PubMedCrossRef 9. Swanton C, Burrell RA: Advances in personalized therapeutics in non-small cell lung cancer: 4q12
amplification, PDGFRA oncogene addiction and sunitinib sensitivity. Cancer Biol Ther 2009, 8:2051–2053.PubMedCrossRef 10. Togano T, Sasaki M, Watanabe M, Nakashima M, Tsuruo T, Umezawa K, Higashihara M, Watanabe T, Horie R: Induction of oncogene addiction shift to NF-kappaB by camptothecin in solid tumor cells. Biochem Biophys Res Commun 2009, 390:60–64.PubMedCrossRef 11. Jin Y, Chen Q, Lu Z, Chen B, Pan J: Triptolide abrogates oncogene FIP1L1-PDGFRalpha addiction and induces apoptosis in hypereosinophilic syndrome. Cancer Sci 2009, 100:2210–2217.PubMedCrossRef 12. Calzolari F, Appolloni I, Tutucci E, Caviglia S, Terrile M, Corte G, Malatesta P: Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia 2008, 10:1373–1382. following 1382.PubMed 13. Rothenberg SM, Engelman JA, Le S, Riese DJ, Haber DA, Settleman J: Modeling oncogene addiction using RNA interference.